Skip to main content
. 2019 May 9;8(6):754–763. doi: 10.1530/EC-19-0045

Table 6.

Association between response to RAI therapy and BRAFV600E status in PTC patients with high recurrence risk.

Response to therapy BRAFV600E mutant group BRAFV600E wild-type group P value
Excellent response 148 (47.7%) 32 (48.5%) 0.498
Indeterminate response 42 (13.5%) 5 (7.6%)
Biochemical incomplete response 19 (6.1%) 3 (4.5%)
Structural incomplete response 101 (32.6%) 26 (39.4%)